[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-thromboembolisms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-thromboembolisms":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,82,105,130,159,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100627775","electrical-impedance-tomography-for-assessment-of-pulmonary-hypertension-100627775",false,"NCT07453017","Electrical Impedance Tomography for Assessment of Pulmonary Hypertension","Assessment of Pulmonary Artery Pressure and Hemodynamic Measurements by Electrical Impedance Tomography and Right Heart Catheterization","Inclusion Criteria:\n\n* Patients with a diagnosis or clinical suspicion of pulmonary arterial hypertension (PAH) and with a medical indication for right heart catheterization.\n* Patients evaluated at the Pulmonology Service of InCor-HCFMUSP.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Structural heart disease, such as atrial septal defect, ventricular septal defect, or valvular disease.\n* Cardiac arrhythmias.\n* Presence of a cardiac pacemaker or other implantable electronic device.\n* Skin lesions at the thoracic region that would prevent placement of the EIT electrode belt.\n* WHO functional class IV of new york heart association (NYAH)..\n* Inability to perform a voluntary respiratory pause (apnea) of at least 30 seconds or inability to understand and follow instructions required.\n* Decline to participate in the study by not signing the informed consent form or refusal by the attending medical team.","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","Pulmonary hypertension is a serious and progressive disease that is difficult to treat and diagnose, mainly because its symptoms are nonspecific and often delay recognition. Early diagnosis is a major challenge. Although several tests may suggest the disease, the definitive diagnosis still requires right heart catheterization, an invasive procedure that directly measures pulmonary hemodynamics such as pulmonary artery pressure, cardiac output, and vascular resistance.\n\nElectrical impedance tomography (EIT) is a non-invasive, radiation-free bedside monitoring method that can evaluate ventilation and pulmonary perfusion. The number of studies investigating perfusion with EIT has been increasing, since the possibility of having a safe, radiation-free, and repeatable method available at the bedside is of great clinical interest in different fields of medicine.\n\nOur hypothesis is that EIT provides information that correlates with the findings of right heart catheterization in patients with suspected pulmonary arterial hypertension (PAH). EIT may serve as a useful screening tool prior to catheterization and may also help in risk stratification of patients with pulmonary hypertension",[26,27],"Pulmonary Hypertension","Pulmonary Thromboembolisms",[29,30,31,32],"Right Heart Catheterization","Electrical Impedance Tomography (EIT)","Pulmonary Vascular Resistance","Cardiac Output","RECRUITING","2026-02-27",{"date":36,"type":37},"2026-03-05","ACTUAL",{"date":39,"type":37},"2024-04-26",{"date":41,"type":20},"2026-12",{"name":43,"class":44},"University of Sao Paulo General Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":52,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":69,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100619962","the-caribbean-registry-of-extracorporeal-membrane-oxygenation-ecmo-from-the-university-hospital-in-martinique-100619962","NCT07351435","The Caribbean Registry of Extracorporeal Membrane Oxygenation (ECMO) From the University Hospital in Martinique","Inclusion Criteria:\n\n* All consecutive patients implanted with a veno-venous extracorporeal membrane oxygenation device or extracorporeal membrane oxygenation device by the HeartTeam from the University Hospital of Martinique (UHM) from January 2010\n\nExclusion Criteria:\n\n* Patients with incomplete data (primary endpoint and less than 80% secondary study outcomes)","90 Years",{"count":54,"type":20},1200,"1 Year","OBSERVATIONAL","The project's main goal is to collect baseline clinical and procedural data as well as to assess clinical outcomes for all patients undergoing VV, VA or VAV ECMO implantation in the French West Indies and Guiana. All patients undergoing ECMO implantation will be prospectively registered.",[59,60,61,62,27,63,64,65,66,67,68],"Cardiogenic Shock","Malignant Arrhythmias","Ischemic or Valvular Heart Failure","Drepanocytosis and Thoracic Syndrome","Sepsis","ARDS (Acute Respiratory Distress Syndrome)","Intoxication","Cardiac Arrest (CA)","Postcardiotomy Heart Failure","Acute Respiratory Failure",[70,71],"acute heart failure","respiratory insufficiency","NOT_YET_RECRUITING","2026-01-09",{"date":75,"type":37},"2026-01-20",{"date":77,"type":20},"2026-02-01",{"date":79,"type":20},"2033-06-30",{"name":81,"class":44},"University of Genova",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100494533","functional-pulmonary-capillary-surface-area-in-bpa-for-cteph-100494533","NCT05719415","Functional Pulmonary Capillary Surface Area in BPA for CTEPH","Assessment of Recovery of Functional Capillary Surface Area in Patients Undergoing a Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension","Inclusion Criteria:\n\n* All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension\n\nExclusion Criteria:\n\n* Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,\n* Presence of patent foramen ovale","75 Years",{"count":91,"type":20},40,[23],"Chronic thromboembolic pulmonary hypertension \\[CTEPH\\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \\[BPA\\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \\[FCSA\\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.",[95,27],"Hypertension, Pulmonary","2025-09-22",{"date":98,"type":37},"2025-09-23",{"date":100,"type":37},"2023-03-23",{"date":102,"type":20},"2028-01-30",{"name":104,"class":44},"Jewish General Hospital",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":45},"100545448","smart-technology-facilitated-patient-centered-care-for-patients-with-pulmonary-thromboembolism-100545448","NCT06382038","Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism","Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism：A Multicenter, Randomized Controlled Trial","SmaPE","Inclusion Criteria:\n\n* Inpatients aged ≥18 years;\n* （2）PTE confirmed through imaging examinations, meeting at least one of the following criteria: a.Newly diagnosed PTE during the current hospitalization; b. Prior PTE with imaging evidence of residual thrombus.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Previous PTE combined with CTEPH;\n* Mental retardation or a combination of other serious illnesses that make them incapable of living on their own;\n* Inability to use smartphones, computer tablets and other smart devices;\n* Being pregnant or breastfeeding;\n* Have participated in similar trials or are undergoing other clinical trials.",{"count":114,"type":20},2972,[23],"Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.\n\nThe objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of pulmonary thromboembolism (PTE) on the long-term outcome of PTE patients, in order to enhance clinical practice and establish a foundation of evidence for managing patients with PTE.",[118,27,119],"Venous Thromboembolism","Digital Health",[118,27,119],"2025-05-27",{"date":123,"type":37},"2025-05-31",{"date":125,"type":20},"2025-10-08",{"date":127,"type":20},"2026-10-31",{"name":129,"class":44},"Navy General Hospital, Beijing",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":139,"studyType":56,"phases":4,"briefSummary":140,"conditions":141,"keywords":146,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":45},"100542868","registry-of-catheter-intervention-in-pulmonary-embolism-100542868","NCT06348459","Registry of Catheter Intervention in Pulmonary Embolism","RiTEP","Inclusion Criteria:\n\n* adult patients (aged 18 years old or older)\n* confirmed diagnosis of acute PE (on computed tomography or echocardiogram plus pulmonary angiography)\n* high-risk PE or intermediate-high risk according to ESC risk stratification in the 2019 guidelines (briefly, elevated cardiac biomarkers \\[troponin or N-terminal pro-B-type natriuretic peptide\\], and right ventricle to left ventricle ratio \\> 0.9 \\[on computed tomography or echocardiogram\\], and PE severity index III to IV or simplified PE severity index=1\n* eligibility for catheter-directed intervention\n\nExclusion Criteria:\n\n* unconfirmed diagnosis of PE\n* undefined risk stratification, and\n* PE with uncertain chronology or beyond seven days of symptom initiation.",{"count":138,"type":20},300,"2 Years","Multicenter longitudinal observational ambispective (retrospective cases from 2014 and prospective from 2018 onwards) cohort study. The registry recruits a series of consecutive patients admitted for moderate-high risk or high-risk pulmonary embolism (according to 2019 European Society of Cardiology guidelines) treated invasively. This study aims to describe the acute management of the safety and effectiveness of different percutaneous interventions for acute pulmonary embolism.",[142,143,144,145,27],"Pulmonary Embolism","Pulmonary Embolism Acute Massive","Pulmonary Embolism Acute","Pulmonary Embolism and Thrombosis",[147,148,149],"Aspiration Thrombectomy","Percutaneous Aspiration Thrombectomy","Local Thrombolysis","2025-04-23",{"date":152,"type":37},"2025-04-25",{"date":154,"type":37},"2018-09-18",{"date":156,"type":20},"2030-12-31",{"name":158,"class":44},"Hospital San Carlos, Madrid",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":45},"100574581","pulmonary-thromboembolism-in-cancer-patients-early-rule-out-from-the-emergency-department-100574581","NCT06761144","Pulmonary Thromboembolism in Cancer Patients: Early Rule-out From the Emergency Department","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of pulmonary embolism (symptomatic and\u002For incidental)\n* Active onco-haematological disease (disease followed in oncological\u002Fhaematological and\u002For metastatic setting)\n* Informed consent to the study\n\nExclusion Criteria:\n\n* Patients returning to the Emergency Department for complications related to previously diagnosed pulmonary embolism",{"count":166,"type":20},500,"Pulmonary thromboembolism is a frequent complication of cancer; in some cases, it is diagnosed occasionally during diagnostic examinations as part of the regular follow-up of the disease. Not all patients diagnosed with thromboembolism present symptoms; therefore, after appropriate investigations during observation in the emergency room and\u002For a short hospitalisation in Emergency Medicine, they could be discharged home, avoiding lengthy hospitalisations that would have a considerable impact on their health and psychological condition.\n\nThe goal of this observational study is to compare the efficacy of several assessment scales for use by physicians to identify patients at low risk of developing serious complications of pulmonary embolism within 30 days of diagnosis, in order to be able to identify a group of low-risk patients who could be discharged early from the emergency department\u002Femergency medicine safely.\n\nWhat does participation in this study entail compared to the normal care you receive and what are your responsibilities as a participant? At the time of patient enrolment in the emergency room\u002Femergency medicine, the data necessary for the calculation of 6 scoring systems will be collected, which will take approximately 5 minutes.\n\nThe patient enrolled in the study will be contacted by telephone in order to assess the state of health; the call will take approximately 1 minute and will take place 30 days after access to the emergency room.\n\nParticipation in the study does not entail any obligation or restriction, nor will it be charged for.",[27],"2024-12-30",{"date":171,"type":37},"2025-01-07",{"date":173,"type":37},"2024-07-13",{"date":175,"type":20},"2027-07-01",{"name":177,"class":44},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":45},"100542312","personalized-anticoagulant-therapy-for-pulmonary-thromboembolism-100542312","NCT06341231","Personalized Anticoagulant Therapy for Pulmonary Thromboembolism","Personalized Anticoagulant Therapy for Pulmonary Thromboembolism in Specific Populations With Older Age, Renal Insufficiency or Co-existing Malignancy","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Adult patients with objectively diagnosed pulmonary thromboembolism (PTE) (with or without concomitant deep vein thrombosis);\n3. Specific populations meeting any of the following criteria: elderly patients (≥75 years old); patients with impaired kidney function (creatinine clearance estimated by the Cockcroft-Gault formula, CrCl \\\u003C 60ml\u002Fmin); patients with active malignancies (under treatment or with unrecovered malignancies);\n4. Patients who have not started anticoagulant therapy before enrollment and are planned for anticoagulant treatment after evaluation by the attending physician;\n5. Ecpected life expectancy longer than 3 months.\n6. Patients who understand and agree to participate in this study, sign the informed consent form, and adhere to regular follow-up visits.\n\nExclusion Criteria:\n\n1. Moderate or severe liver dysfunction (Child-Pugh class B or C);\n2. Spontaneous bleeding tendency, such as coagulation disorders or thrombocytopenia (PLT\\\u003C20×10\\^9\u002FL);\n3. Contraindications to anticoagulant drugs, including allergy to anticoagulants, clinically significant active bleeding, significant risk of major bleeding due to lesions or conditions, significantly abnormal coagulation function, liver disease with clinically relevant bleeding risk, thrombocytopenia, etc., as determined by the attending physician;\n4. High-risk pulmonary embolism requiring thrombolysis;\n5. Patients currently participating in other clinical trials.",{"count":186,"type":20},4700,"The goal of this prospective observational study is to explore the influencing factors of the efficacy and safety of anticoagulant therapy for pulmonary thromboembolism in special populations with older age, renal insufficiency or co-existing malignancy, and establish a predictive model to guide clinical practice. The main questions it aims to answer are:\n\n* To analyze the influencing factors of the efficacy and safety of anticoagulant therapy for specific populations with pulmonary thromboembolism (PTE) in the real world (such as the elderly, those with impaired kidney function, and individuals with malignant tumors).\n* Whether we can use machine-learning models to predict bleeding events and VTE recurrence in special populations following anticoagulant therapy in the real world? Participants will receive diagnostic and therapeutic measures for pulmonary thromboembolism in accordance with clinical guidelines, including anticoagulant therapy. Some patients need to have peripheral blood samples collected at the time of enrollment and 3 months after anticoagulant therapy.",[27,189],"Anticoagulants; Increased","2024-03-31",{"date":192,"type":37},"2024-04-02",{"date":194,"type":37},"2024-02-01",{"date":196,"type":20},"2027-12-31",{"name":198,"class":44},"Xiangya Hospital of Central South University"]